M
Maddalena Paganin
Researcher at University of Padua
Publications - 28
Citations - 1311
Maddalena Paganin is an academic researcher from University of Padua. The author has contributed to research in topics: Leukemia & Minimal residual disease. The author has an hindex of 15, co-authored 27 publications receiving 1030 citations. Previous affiliations of Maddalena Paganin include University of Milan.
Papers
More filters
Journal ArticleDOI
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Gannie Tzoneva,Arianne Perez-Garcia,Zachary Carpenter,Hossein Khiabanian,Valeria Tosello,Maddalena Allegretta,Elisabeth Paietta,Janis Racevskis,Jacob M. Rowe,Jacob M. Rowe,Martin S. Tallman,Maddalena Paganin,Giuseppe Basso,Jana Hof,Renate Kirschner-Schwabe,Teresa Palomero,Raul Rabadan,Adolfo A. Ferrando +17 more
TL;DR: A prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL is supported.
Journal ArticleDOI
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia
Koichi Oshima,Hossein Khiabanian,Hossein Khiabanian,Ana C. da Silva-Almeida,Gannie Tzoneva,Francesco Abate,Alberto Ambesi-Impiombato,Marta Sanchez-Martin,Zachary Carpenter,Alex Penson,Arianne Perez-Garcia,Cornelia Eckert,Cornelia Eckert,Concepcion Nicolas,Milagros Balbín,Maria Luisa Sulis,Motohiro Kato,Katsuyoshi Koh,Maddalena Paganin,Giuseppe Basso,Julie M. Gastier-Foster,Meenakshi Devidas,Mignon L. Loh,Renate Kirschner-Schwabe,Renate Kirschner-Schwabe,Teresa Palomero,Teresa Palomero,Raul Rabadan,Adolfo A. Ferrando,Adolfo A. Ferrando +29 more
TL;DR: The central role of chemotherapy-driven selection as a central mechanism of leukemia clonal evolution in relapsed ALL is highlighted, and a previously unrecognized dual role of RAS mutations as drivers of both sensitivity and resistance to chemotherapy is demonstrated.
Journal ArticleDOI
WT1 mutations in T-ALL
Valeria Tosello,Marc R. Mansour,Kelly Barnes,Maddalena Paganin,Maria Luisa Sulis,Sarah Jenkinson,Christopher Allen,Rosemary E. Gale,David C. Linch,Teresa Palomero,Teresa Palomero,Pedro J. Real,Vundavalli V. Murty,Xiaopan Yao,Susan M. Richards,Anthony H. Goldstone,Jacob M. Rowe,Giuseppe Basso,Peter H. Wiernik,Peter H. Wiernik,Elisabeth Paietta,Elisabeth Paietta,Rob Pieters,Martin A. Horstmann,Jules P.P. Meijerink,Adolfo A. Ferrando,Adolfo A. Ferrando +26 more
TL;DR: WT1 mutations are most prominently found in T-ALL cases with aberrant rearrangements of the oncogenic TLX1, TLX3, and HOXA transcription factor oncogenes, and survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-all.
Journal ArticleDOI
Genetic loss of SH2B3 in acute lymphoblastic leukemia
Arianne Perez-Garcia,Alberto Ambesi-Impiombato,Michael Hadler,Isaura Rigo,Charles A. LeDuc,Kara M. Kelly,Chaim Jalas,Elisabeth Paietta,Janis Racevskis,Jacob M. Rowe,Jacob M. Rowe,Martin S. Tallman,Maddalena Paganin,Giuseppe Basso,Wei Tong,Wendy K. Chung,Adolfo A. Ferrando,Adolfo A. Ferrando +17 more
TL;DR: A Knudson tumor suppressor role for SH2B3 in the pathogenesis of ALL is demonstrated and a possible link between genetic predisposition factors in thepathogenesis of autoimmunity and leukemogenesis is highlighted.
Journal ArticleDOI
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia
Gannie Tzoneva,Chelsea L. Dieck,Koichi Oshima,Alberto Ambesi-Impiombato,Marta Sanchez-Martin,Chioma J. Madubata,Hossein Khiabanian,Jiangyan Yu,Esmé Waanders,Ilaria Iacobucci,Maria Luisa Sulis,Motohiro Kato,Katsuyoshi Koh,Maddalena Paganin,Giuseppe Basso,Julie M. Gastier-Foster,Mignon L. Loh,Renate Kirschner-Schwabe,Charles G. Mullighan,Raul Rabadan,Adolfo A. Ferrando +20 more
TL;DR: The fitness cost of NT5C2 mutation and resistance to chemotherapy as key evolutionary drivers that shape clonal evolution in relapsed ALL are identified and support a role for IMPDH inhibition in the treatment of ALL.